[ad_1]
SAN FRANCISCO, Oct. 20 (Xinhua) – American scientists at the University of California at San Francisco (UCSF) have come up with a new drug that can restore the function of a heart tissue devoid of blood pressure. Oxygen in conditions of hypoxia, according to the results of a new study published this weekend
The new drug called OMX-CV was developed by Omniox, Inc., l & # 39; One of the very first biotech startups to be launched in the incubator space of UCSF's Mission Bay campus in 2010. [19659002] The biopharmaceutical company has developed treatment therapies. administration of oxygen for the treatment of cancer, cardiovascular diseases, trauma and other conditions in which low levels of oxygen or hypoxia have a negative impact on the results of disease.
The new drug does not cause a systemic face. excessive or excessive effects with excessive oxygenation of the blood, which may itself be toxic. He delivers his precious cargo of oxygen only to the tissues that need it the most.
UCSF researchers tested the treatment and discovered that the new oxygen delivery therapy was able to restore the function of oxygen-free cardiac tissue in a model animal of global hypoxia.
Their findings were published in the journal PLOS Biology on Thursday.
The tissues of the human body can suffer significant damage if they lack oxygen, and such hypoxic conditions can lead to long-term tissue damage. or even heart attacks.
"Any treatment whose blood flow is compromised, whether as a result of trauma, stroke, or heart disease, could potentially be targeted by treatment of this type, "said Emin Maltepe, badociate professor of pediatrics at UCSF's lead author of the study.
Unlike hemoglobin-based drugs that sometimes pump excess oxygen into the bloodstream, which produces undesirable side effects, OMX-CV eliminates these problems by using a bacterial protein. base, rather than hemoglobin, was H-NOX.
Maltepe and his team modified the chemical structure of H-NOX proteins and reconfigured them to remain oxygen-tight while leaving nitric oxide alone.
Modified proteins tightly bind oxygen until they encounter severely hypoxic tissue and release much needed oxygen.
"OMX-CV is set to release oxygen only under pathological conditions … Relatively low doses of the drug transform the capacity of Ana Krtolica, vice president of research at Omniox and co-author of the study, said: "The heart to follow in the face of severe hypoxia."
US scientists also hope that the OMX-CV model can be applied to pediatric medical care, especially when it is used as a medicine providing oxygen to alleviate the physical stress badociated with hypoxia and improve recovery after a heart attack or after an open heart operation in the adult and the child.
Source link
